Drug intelligence / Profile preview

PNQ-103

Development stage: Preclinical
Lead developer: Portage Biotech
Modality: Small Molecules
Administration: Oral

Overview

PNQ-103 is a small molecule antagonist of the A2B adenosine receptor (A2BAR) developed by Impetis Biosciences. It is designed to block adenosine-mediated immune suppression in the tumor microenvironment, making it a potential treatment for immune-resistant cancers. Additionally, it is being explored for orphan indications such as sickle cell disease (SCD). PNQ-103-1 is a prodrug formulation of the compound. Impetis Biosciences has granted an exclusive license for the platform to Tarus Therapeutics. The program is currently at the IND-ready stage.

Targets

ADORA2B (Adenosine A2B receptor)

Beyond the preview

Go deeper on PNQ-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PNQ-103.

Explore the full profile